Publication Topic

Sacks NC, Ash AS, Ghosh K, Rosen AK, Wong JB, Rosen AB. 2015. Implications of ignoring growing proportions of hospitalizations with acute myocardial infraction. Am Heart J, December 2015.

Wu C, Fortier KJ, LaPensee K, Fan W, Mitchell M, Cyr PL, Jensen IS. A US hospital economic impact model for oritavancin in ABSSSI patients with risk of MRSA infections. Abstract PSS10, ISPOR 17th Annual European Congress 2014.

Jensen IS, Bay C, Cyr PL. Estimating the impact of combining cangrelor and bivalirudin to a U.S. hospital performing PCI procedures. ISPOR 18^th Annual International Meeting, New Montreal Quebec, 2014.

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16^th Annual European Congress, Amsterdam, Netherlands, 2014.

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.

Jensen IS, Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin’s lymphoma in the United States: A budgetary impact analysis. Abstract C14, Academy of Managed Care Pharmacy 26^th Annual Meeting & Expo, 2014.

Jensen IS, Halbert RJ, Grosvenor A, Swartz E, Rossi G, Naoshy S, et al. Incorporating stakeholder input into budget impact models to compare stem cell mobilization strategies. Abstract PCN43, ISPOR 18th Annual International Meeting, 2013.

Kuan RK, Janssen R, Heyward W, Nordyke RJ. 2013. Cost-effectiveness of hepatitis B vaccination using HEPLISAV^TM in selected adults compared to Engerix-B^® vaccine. Vaccine 31(37):4024-32; doi: 10.1016/j.vaccine.2013.05.014. PMID: 23707166.